Sanjay Malhotra
Affiliations: | Stanford University, Palo Alto, CA |
Area:
Radiation OncologyGoogle:
"Sanjay Malhotra"Mean distance: 106866
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Rice MA, Kumar V, Tailor D, et al. (2022) SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer. Cell Reports. Medicine. 3: 100502 |
| Eldhose B, Pandrala M, Xavier C, et al. (2021) New Selective Inhibitors of ERG Positive Prostate Cancer: ERGi-USU-6 Salt Derivatives. Acs Medicinal Chemistry Letters. 12: 1703-1709 |
| Singh R, Kumar R, Pandrala M, et al. (2021) Facile synthesis of C6-substituted benz[4,5]imidazo[1,2-a]quinoxaline derivatives and their anticancer evaluation. Archiv Der Pharmazie. e2000393 |
| Rice MA, Malhotra SV, Stoyanova T. (2019) Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. Frontiers in Oncology. 9: 801 |
| Tailor D, Resendez A, Kumar V, et al. (2019) Abstract 5275: Cancer specific caloric restriction using novel small molecule improves the therapeutic regime for triple negative breast cancer Cancer Research. 79: 5275-5275 |
| Going CC, Tailor D, Kumar V, et al. (2018) Quantitative proteomic profiling reveals key pathways in the anti-cancer action of methoxychalcone derivatives in triple negative breast cancer. Journal of Proteome Research |
| Mohamed AA, Xavier CP, Sukumar G, et al. (2018) Identification of a small molecule that selectively inhibits ERG-positive cancer cell growth. Cancer Research |
| Ferroni C, Pepe A, Kim YS, et al. (2017) 1,4-Substituted Triazoles as Non-Steroidal Antiandrogens for Prostate Cancer Treatment. Journal of Medicinal Chemistry |
| Mohamed AA, Xavier CP, Sukumar G, et al. (2017) Abstract 1183: Structure-activity studies and biological evaluations of ERGi-USU, a highly selective inhibitor for ERG-positive prostate cancer cells Cancer Research. 77: 1183-1183 |
| Mohamed A, Xavier C, Sukumar G, et al. (2017) MP87-14 STRUCTURE-ACTIVITY RELATIONSHIP STUDIES OF ERGI-USU, A HIGHLY SELECTIVE INHIBITOR FOR ERG POSITIVE PROSTATE CANCER CELLS Journal of Urology. 197 |